VIR - Vir Biotechnology GAAP EPS of $1.30 beats by $1.37 revenue of $374.6M beats by $260.32M
- Vir Biotechnology press release ( NASDAQ: VIR ): Q3 GAAP EPS of $1.30 beats by $1.37 .
- Revenue of $374.6M (+261.6% Y/Y) beats by $260.32M .
- As of September 30, 2022, excluding restricted cash, the Company had approximately $2.7B in cash, cash equivalents, investments and profit-share payments to be received from GSK.
For further details see:
Vir Biotechnology GAAP EPS of $1.30 beats by $1.37, revenue of $374.6M beats by $260.32M